Details for Patent: 6,783,753
✉ Email this page to a colleague
Title: | Delivery of antidepressants through an inhalation route |
Abstract: | The present invention relates to the delivery of antidepressants through an inhalation route. Specifically, it relates to aerosols containing an antidepressant that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antidepressant. In a method aspect of the present invention, an antidepressant is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an antidepressant to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an antidepressant through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an antidepressant; and, b) a device that forms an antidepressant containing aerosol from the composition, for inhalation by the mammal. |
Inventor(s): | Rabinowitz; Joshua D. (Mountain View, CA), Zaffaroni; Alejandro C. (Atherton, CA) |
Assignee: | ALEXZA Molecular Delivery Corporation (Palo Alto, CA) |
Filing Date: | May 16, 2002 |
Application Number: | 10/151,626 |
Claims: | 1. A composition for delivery of an antidepressant drug comprising a condensation aerosol a) formed by volatizing an antidepressant drug under conditions effective to produce a heated vapor of the drug and condensing the heated vapor of the drug to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less than 5% antidepressant drug degradation products, and c) the aerosol has an MMAD less than 3 microns. 2. A composition for delivery of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, valproic acid, or protryptyline comprising a condensation aerosol a) formed by volatizing bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, valproic acid, or protryptyline under conditions effective to produce a heated vapor of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, valproic acid, or protrvotyline and condensing the heated vapor of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, valproic acid, or protryptyline to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less than 5% bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, valproic acid, or protryptyline drug degradation products, and c) the aerosol has an MMAD less than 3 microns. 3. The composition according to claim 2, wherein the condensation aerosol particles comprise at least 90 percent by weight of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, valproic acid, or protryptyline. 4. The composition according to claim 3, wherein the geometric standard deviation around the mass median aerodynamic diameter of the aerosol is less than 2.5. 5. The composition according to claim 3, wherein the condensation aerosol particles comprise at least 95 percent by weight of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, noriryptiline, valproic acid, or protryptyline. 6. A method of producing an antidepressant drug in an aerosol form comprising: a) volatilizing an antidepressant drug under conditions effective to produce a heated vapor of the drug, and b) during said volatilizing, passing air through the heated vapor to produce aerosol particles of the drug comprising less than 5% antidepressant drug degradation products and an aerosol having an MMAD less than 3 .mu.m. 7. A method of producing bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, vaiproic acid, or protryptyline in an aerosol form comprising: a) volatilizing bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptyline, valproic acid, or protryptyline under conditions effective to produce a heated vapor of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, valproic acid, or protryotyline, and b) during said volatilizing, passing air through the heated vapor to produce aerosol particles of the bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluroxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, valproic acid, or protryptyline comprising less than 5% bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, valproic acid, or protryptyline degradation products and an aerosol having an MMAD less than 3 .mu.m. 8. The method according to claim 6, wherein the aerosol particles are formed at a rate of greater than 0.5 mg/sec. 9. The method according to claim 6, wherein said volatilizing includes heating a film, which includes the antidepressant drug and is on a solid support having the surface texture of a metal foil, to a temperature sufficient to volatilize the drug from the film. 10. The method according to claim 7, wherein the aerosol particles comprise at least 90 percent by weight of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, vaiproic acid, or protryptyline. 11. The method according to claim 10, wherein the geometric standard deviation around the mass median aerodynamic diameter of the aerosol is less than 2.5. 12. The method according to claim 11, wherein the aerosol particles comprise at least 95 percent by weight of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, valproic acid, or protryptyline. 13. The method according to claim 7, wherein said volatilizing includes heating a film, which includes bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxarnine, mirtazepine, paroxetine, sertraline, amoxapane, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, vaiproic acid, or protryptyline and is on solid support having the surface texture of a metal foil, to a temperature sufficient to volatilize the bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortryptiline, valproic acid, or protryptyline from the film. |